China SFDA Encourages Regulatory Consultations In New Communication Guidelines
This article was originally published in PharmAsia News
China hopes strengthened communication with sponsors will spur innovation and new drug approvals.
You may also be interested in...
A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.